H.C. Wainwright analyst Matthew Caufield initiated coverage of Surrozen (SRZN) with a Buy rating and $32 price target Surrozen is advancing novel therapies based on the selective modulation of the Wingless-related integration site pathway, the analyst tells investors in a research note. The firm says the company is developing tissue-specific antibodies that could leverage the body’s biological repair and regeneration mechanisms.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRZN:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue